title: Pluripotent stem cells: the last 10 years.
abstract: Pluripotent stem cells (PSCs) can differentiate into virtually any cell type in the body, making them attractive for both regenerative medicine and drug discovery. Over the past 10 years, technological advances and innovative platforms have yielded first-in-man PSC-based clinical trials and opened up new approaches for disease modeling and drug development. Induced PSCs have become the foremost alternative to embryonic stem cells and accelerated the development of disease-in-a-dish models. Over the years and with each new discovery, PSCs have proven to be extremely versatile. This review article highlights key advancements in PSC research, from 2006 to 2016, and how they will guide the direction of the field over the next decade.
authors.affiliation: Astellas Institute for Regenerative Medicine, 33 Locke Drive, Marlborough, MA 01752, USA.
authors.forename: Erin A
authors.initials: EA
authors.lastname: Kimbrel
authors.affiliation: Astellas Institute for Regenerative Medicine, 33 Locke Drive, Marlborough, MA 01752, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Lanza
mesh_terms: D000818:Animals; D006801:Humans; D039904:Pluripotent Stem Cells / Q000166:cytology*; D044968:Regenerative Medicine; D033581:Stem Cell Transplantation; D023822:Tissue Engineering / Q000379:methods*
keywords: clinical trials; disease-in-a-dish models; drug screening; embryonic stem cells; gene editing; induced pluripotent stem cells